European patent loss for Forward Pharma related to MS fumarate drug

SeekingAlpha reports a European patent decision related to the MS drug Tecfidera (relevant ingredient dimethyl fumarate):


The European Patent Office has revoked Forward Pharma A/S's EP 2801355 patent ('355 patent) following challenges from several parties. The company says its is disappointed with the decision and plans to appeal.



This may impact royalties Forward would get from Biogen. Recall



In February 2017, Biogen paid Forward $1.25B to settle their dispute over a patent covering methods of treating MS with 480 mg of DMF. Biogen also received an irrevocable co-exclusive license to Forward's IP in the U.S.


link: https://seekingalpha.com/news/3326083-forward-pharma-loses-challenge-european-patent-covering-dimethyl-fumarate-tecfidera-royalties